NasdaqHealth CareHealth Care SuppliesS&P MidCap 400
$9.46
-0.63 (-6.24%)
Close of Nov 06, 2026 · end-of-day data
XRAY 8-K filings in 2025
Every material Form 8-K Dentsply Sirona filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On December 24, 2025, Dentsply Sirona obtained lender consent and signed amendments to its JPMorgan-agented revolving credit facility and three note purchase agreements. The changes replace the prior leverage covenants with new Total Leverage and Senior Leverage Ratio limits, cap efficiency-initiative EBITDA addbacks at $75 million through December 31, 2026, and add a new covenant restricting Restricted Payments, subject to exceptions.
Amendments dated December 24, 2025 cover the revolving credit facility with JPMorgan Chase Bank, N.A. as administrative agent and three note purchase agreements.
Total Leverage Ratio cap is 4.25 to 1.00 for quarters ending December 31, 2025 through June 30, 2026, stepping down to 3.50 to 1.00 from September 30, 2027.
Senior Leverage Ratio cap is 3.25 to 1.00 through June 30, 2026, stepping down to 2.50 to 1.00 from September 30, 2027.
EBITDA addbacks for efficiency initiatives are capped at $75 million in the aggregate for quarters ending December 31, 2025 through December 31, 2026.
Dentsply Sirona reported third-quarter 2025 net sales of $904 million, down 5.0% from a year earlier, and a GAAP net loss attributable to the company of $427 million, or $2.14 per share, which included a $263 million non-cash impairment charge. The company revised its 2025 outlook to net sales of $3.6 billion to $3.7 billion and adjusted EPS of about $1.60, and said CFO Matt Garth has departed, which shareholders should weigh against the company's Return-to-Growth plan.
Q3 2025 net sales were $904 million, down 5.0% as reported and down 8.0% in constant currency.
GAAP net loss attributable to Dentsply Sirona was $427 million ($2.14 per share), versus a $494 million loss ($2.46 per share) a year earlier; adjusted EPS was $0.37 versus $0.50.
Revised 2025 outlook: net sales of $3.6 billion to $3.7 billion and adjusted EPS of about $1.60.
CFO Matt Garth departed; Dustin Shields was named Chief Transformation Officer effective December 1, 2025.
DENTSPLY SIRONA said Chief Financial Officer Matthew E. Garth will leave the role effective November 5, 2025, and that the company has started a search for a successor. CEO Daniel T. Scavilla has been appointed interim principal financial officer for SEC filings, effective upon Garth's departure. The company said Garth's exit was not due to any disagreement over financial statements, internal controls, or accounting practices.
Matthew E. Garth ceases to serve as Executive Vice President and Chief Financial Officer effective November 5, 2025; decision made October 31, 2025
Daniel T. Scavilla, President and CEO, named interim principal financial officer, effective upon Garth's departure
Company has initiated a search for a permanent Chief Financial Officer; no new compensatory arrangements for Scavilla in the interim role
Company says the departure involved no disagreement on financial statements, internal controls, or accounting principles
DENTSPLY SIRONA said its Executive Vice President, Corporate Development, General Counsel and Secretary, Richard C. Rosenzweig, will leave that role by mutual agreement effective October 3, 2025. He will serve as Special Legal Advisor through March 4, 2026 under a transition agreement that sets severance and consulting terms. The change is an executive transition with defined payments rather than a change in financial results.
Rosenzweig's general counsel and corporate development roles end October 3, 2025; he becomes Special Legal Advisor through March 4, 2026 or earlier termination.
Transition agreement, dated October 2, 2025, provides a $30,000 monthly fixed fee for his Special Legal Advisor services, paid in full if terminated before March 4, 2026 for reasons other than Cause.
After the Separation Date, the company will engage him as an independent contractor consultant for one year at $20,000 per month.
DENTSPLY SIRONA's Compensation & Human Capital Committee approved a one-time retention equity award for several executives, including Senior Vice President and Chief Supply Chain Officer Tony Johnson. The award, made in stock options with a grant date fair value of $2,000,000, is intended to recognize his work during the recent CEO and CFO transitions and to encourage him to stay with the company for three years.
Award to Tony Johnson is stock options with a grant date fair value of $2,000,000
Options cliff-vest on the third anniversary of the grant date if he remains employed through that date
Grant expected on the second trading day after the Form 10-Q for the quarter ended September 30, 2025 is filed
Half the options have an exercise price equal to fair market value on the grant date; the other half are priced at 110% of that value
Dentsply Sirona reported second-quarter 2025 net sales of $936 million, down 4.9% from a year earlier, and a GAAP net loss of $45 million, or $0.22 per share, driven by a $214 million net-of-tax goodwill and intangible impairment. Adjusted EPS rose to $0.52 from $0.49, and the company reaffirmed its 2025 outlook, though sales and the impairment charge weigh on the picture for shareholders.
Net sales of $936 million fell 4.9% from $984 million; down 6.7% in constant currency, with United States sales down 18.3%.
GAAP net loss attributable to Dentsply Sirona of $45 million, or $0.22 per share, versus a $4 million loss ($0.02 per share) in the second quarter of 2024.
Adjusted EPS of $0.52 compared with $0.49; 2025 outlook maintained at net sales of $3.60 billion to $3.70 billion and adjusted EPS of $1.80 to $2.00.
Dan Scavilla became CEO effective August 1, 2025; quarterly dividend of $0.16 per share is payable October 10, 2025.
Dentsply Sirona said its board appointed Daniel Scavilla, a director since February 2025 and former Globus Medical CEO, as president and chief executive officer effective August 1, 2025, succeeding Simon Campion, who leaves on July 31, 2025. The company also issued preliminary second quarter 2025 results and reaffirmed its 2025 outlook, which gives shareholders a clearer view of the leadership transition and near-term results, though the filing gives no prior-year comparison.
Preliminary second quarter 2025 net sales are expected to be approximately $935 million, with adjusted EPS between $0.50 and $0.52.
The company reaffirmed its 2025 outlook from its May 8, 2025 earnings release and plans to report second quarter results on August 7, 2025.
Scavilla will receive an annual base salary of $1,030,000 and a target bonus of 135% of base salary; Campion resigned from the board effective July 20, 2025, reducing its size from eleven to ten members.
DENTSPLY SIRONA issued $550 million of 8.375% junior subordinated notes due 2055 on June 12, 2025, and used part of the proceeds to repay in full its $435 million 364-day bridge loan, which has been terminated. The filing states no early termination penalties or prepayment premiums were incurred. The deal replaces short-term bridge borrowing with long-dated debt that carries a fixed rate until 2030 and a reset thereafter.
$550 million of 8.375% Fixed-to-Fixed Reset Rate Junior Subordinated Notes due September 12, 2055 issued June 12, 2025
Fixed 8.375% rate until September 12, 2030; thereafter resets to five-year U.S. Treasury rate plus 4.379%, with a floor of 8.375%
$435 million 364-day term loan (Bridge Loan Facility) repaid in full and terminated, with no early termination penalties
Company may redeem the notes at par plus accrued interest starting 90 days before the First Reset Date
On June 3, 2025, DENTSPLY SIRONA obtained lender consent to amend its revolving credit facility with JPMorgan Chase Bank, N.A., and signed amendments to three note purchase agreements. The changes set a 60% cap on senior debt to capitalization, raise the maximum consolidated leverage ratio to 65%, and add interest rate adjustments if the company's credit rating falls below investment grade. The amendments take effect only after certain conditions are met, and the filing does not give the size of any borrowing or interest rate change.
June 3, 2025: lender consent obtained under revolving credit facility dated May 12, 2023, with JPMorgan Chase Bank, N.A. as administrative agent
Maximum allowable consolidated leverage ratio increased to 65%; senior debt to capitalization must not exceed 60%
Note Purchase Agreement Amendment No. 3 signed for three note agreements, dated 2015, 2016 (with Sirona Dental Services GmbH) and 2019
Interest rate adjustments apply if the company's credit rating is downgraded below investment grade
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Dentsply Sirona filing is on SEC EDGAR ↗. 8-K briefs of other companies →